Every week, MedCity News highlights the best of its MedCitizens: syndication partners and MedCity News readers who contribute to MedCityNews.com. The MedCitizens are sponsored by MyPRGenie, the only Do-It-Yourself, PR platform and news wire that gives you access to more than 540,000 journalist contacts.
Now here’s the best of what YOU had to say:
- Certified registered nurse anesthetists: out to replace MDs? “It isn’t difficult to see where all this is heading. The cost of healthcare must be controlled to prevent bankrupting our country.”
- Despite ‘user fees,’ FDA device approval slows. “It takes 20 percent longer to obtain a final decision on a 510(k) submission than it did in 2002, despite the millions the Food & Drug Administration has collected from medical device makers in so-called ‘user fees.'”
- FDA guidance can confuse medical device makers. “Rather than providing predictability and certainty and a roadmap for our companies, it’s actually confused our companies and has made things actually more challenging in terms of getting products cleared for market.”
- 5 helpful facts about the uninsured. “It’s surprisingly easy to run up bills in the thousands of dollars or beyond and also to lose health insurance during an illness.”
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
